A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma

(2019) Leung Li et al.   Cancer Management and Research

Clinical and Therapeutic Implications of Cancer Stem Cells

(2019) Michael F. Clarke   NEW ENGLAND JOURNAL OF MEDICINE

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

(2018) D A Yardley et al.   ANNALS OF ONCOLOGY

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

(2018) Elisa Gobbini et al.   EUROPEAN JOURNAL OF CANCER

Cancer stem cell pipeline flounders

(2018) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

CXCR1/2 pathways in paclitaxel-induced neuropathic pain

(2017) Brandolini Laura et al.   Oncotarget

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells

(2014) Debangshu Samanta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

(2013) A. F. Schott et al.   CLINICAL CANCER RESEARCH

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms

(2012) J. K. Singh et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Variations in Interleukin-8 and Interleukin-10 Are Associated With Pain, Depressed Mood, and Fatigue in Lung Cancer Patients

(2012) Cielito C. Reyes-Gibby et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

(2012) G. R. Oxnard et al.   JNCI-Journal of the National Cancer Institute

CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

(2011) Michael O. Idowu et al.   HUMAN PATHOLOGY

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

(2010) Christophe Ginestier et al.   JOURNAL OF CLINICAL INVESTIGATION

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

(2009) E. Charafe-Jauffret et al.   CLINICAL CANCER RESEARCH